Related Experiment Video

Updated: May 22, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced

Cassandra D Josephson1, Suzanne Granger, Susan F Assmann

  • 1Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.

Blood
|April 28, 2012
PubMed

Insights

Children experienced significantly higher bleeding risks and more bleeding days than adults, irrespective of prophylactic platelet dose. This suggests factors beyond platelet counts contribute to pediatric bleeding in hypoproliferative thrombocytopenia.

Area of Science:

  • Hematology
  • Pediatric Medicine
  • Clinical Trials

Background:

  • Hospitalized patients with treatment-induced hypoproliferative thrombocytopenia often require platelet transfusions.
  • The optimal prophylactic platelet dose for preventing bleeding in these patients remains under investigation.
  • Age-related differences in bleeding risk and transfusion response are not fully understood.

Purpose of the Study:

  • To evaluate the relationship between prophylactic platelet dose and bleeding in pediatric and adult patients.
  • To compare bleeding risk and transfusion outcomes between different age groups.
  • To identify factors contributing to bleeding in patients with hypoproliferative thrombocytopenia.

Main Methods:

  • A randomized trial (PLADO) assigned patients to three prophylactic platelet doses (1.1, 2.2, or 4.4 × 10(11) platelets/m(2)).
  • Daily hemostatic assessments were performed.
  • Primary endpoint was grade 2 or higher World Health Organization bleeding, analyzed across age groups (children 0-18 years, adults).

Main Results:

  • Platelet dose did not predict bleeding risk in any age group.
  • Children exhibited a significantly higher incidence of grade 2 or higher bleeding compared to adults (86-88% in pediatric groups vs. 67% in adults).
  • Pediatric patients experienced more days with significant bleeding (median 3 days vs. 1 day in adults; P < .001), particularly autologous transplant recipients.

Conclusions:

  • Pediatric patients face a higher risk of bleeding than adults, independent of platelet dose, in the context of hypoproliferative thrombocytopenia.
  • Factors other than platelet count likely contribute to the increased bleeding risk observed in children.
  • Age-specific strategies may be necessary to manage bleeding risk in pediatric patients undergoing treatment for thrombocytopenia.

More Related Videos

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...